253 related articles for article (PubMed ID: 21881048)
1. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.
Rossi D; Deaglio S; Dominguez-Sola D; Rasi S; Vaisitti T; Agostinelli C; Spina V; Bruscaggin A; Monti S; Cerri M; Cresta S; Fangazio M; Arcaini L; Lucioni M; Marasca R; Thieblemont C; Capello D; Facchetti F; Kwee I; Pileri SA; Foà R; Bertoni F; Dalla-Favera R; Pasqualucci L; Gaidano G
Blood; 2011 Nov; 118(18):4930-4. PubMed ID: 21881048
[TBL] [Abstract][Full Text] [Related]
2. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.
Ruiz-Ballesteros E; Mollejo M; Rodriguez A; Camacho FI; Algara P; Martinez N; Pollán M; Sanchez-Aguilera A; Menarguez J; Campo E; Martinez P; Mateo M; Piris MA
Blood; 2005 Sep; 106(5):1831-8. PubMed ID: 15914563
[TBL] [Abstract][Full Text] [Related]
3. NF-κB deregulation in splenic marginal zone lymphoma.
Spina V; Rossi D
Semin Cancer Biol; 2016 Aug; 39():61-7. PubMed ID: 27503810
[TBL] [Abstract][Full Text] [Related]
4. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.
Clipson A; Wang M; de Leval L; Ashton-Key M; Wotherspoon A; Vassiliou G; Bolli N; Grove C; Moody S; Escudero-Ibarz L; Gundem G; Brugger K; Xue X; Mi E; Bench A; Scott M; Liu H; Follows G; Robles EF; Martinez-Climent JA; Oscier D; Watkins AJ; Du MQ
Leukemia; 2015 May; 29(5):1177-85. PubMed ID: 25428260
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
[TBL] [Abstract][Full Text] [Related]
6. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis of splenic and nodal marginal zone lymphoma.
Spina V; Rossi D
Best Pract Res Clin Haematol; 2017; 30(1-2):5-12. PubMed ID: 28288716
[TBL] [Abstract][Full Text] [Related]
8. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
Rossi D; Trifonov V; Fangazio M; Bruscaggin A; Rasi S; Spina V; Monti S; Vaisitti T; Arruga F; Famà R; Ciardullo C; Greco M; Cresta S; Piranda D; Holmes A; Fabbri G; Messina M; Rinaldi A; Wang J; Agostinelli C; Piccaluga PP; Lucioni M; Tabbò F; Serra R; Franceschetti S; Deambrogi C; Daniele G; Gattei V; Marasca R; Facchetti F; Arcaini L; Inghirami G; Bertoni F; Pileri SA; Deaglio S; Foà R; Dalla-Favera R; Pasqualucci L; Rabadan R; Gaidano G
J Exp Med; 2012 Aug; 209(9):1537-51. PubMed ID: 22891273
[TBL] [Abstract][Full Text] [Related]
9. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.
Martínez N; Almaraz C; Vaqué JP; Varela I; Derdak S; Beltran S; Mollejo M; Campos-Martin Y; Agueda L; Rinaldi A; Kwee I; Gut M; Blanc J; Oscier D; Strefford JC; Martinez-Lopez J; Salar A; Sole F; Rodriguez-Peralto JL; Diez-Tascón C; García JF; Fraga M; Sebastián E; Alvés J; Menárguez J; González-Carreró J; Casado LF; Bayes M; Bertoni F; Gut I; Piris MA
Leukemia; 2014 Jun; 28(6):1334-40. PubMed ID: 24296945
[TBL] [Abstract][Full Text] [Related]
11. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.
Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527
[TBL] [Abstract][Full Text] [Related]
12. The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.
Jung H; Yoo HY; Lee SH; Shin S; Kim SC; Lee S; Joung JG; Nam JY; Ryu D; Yun JW; Choi JK; Ghosh A; Kim KK; Kim SJ; Kim WS; Park WY; Ko YH
Oncotarget; 2017 Mar; 8(10):17038-17049. PubMed ID: 28152507
[TBL] [Abstract][Full Text] [Related]
13. Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.
Hyeon J; Lee B; Shin SH; Yoo HY; Kim SJ; Kim WS; Park WY; Ko YH
Mod Pathol; 2018 Sep; 31(9):1418-1428. PubMed ID: 29765142
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential.
Yamato A; Soda M; Ueno T; Kojima S; Sonehara K; Kawazu M; Sai E; Yamashita Y; Nagase T; Mano H
Cancer Sci; 2015 Sep; 106(9):1137-42. PubMed ID: 26094954
[TBL] [Abstract][Full Text] [Related]
15. Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor κB and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells.
Tan BM; Zammit NW; Yam AO; Slattery R; Walters SN; Malle E; Grey ST
Diabetologia; 2013 Mar; 56(3):520-32. PubMed ID: 23250032
[TBL] [Abstract][Full Text] [Related]
16. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F
Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598
[TBL] [Abstract][Full Text] [Related]
17. Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2.
Conze DB; Zhao Y; Ashwell JD
PLoS Biol; 2010 Oct; 8(10):e1000518. PubMed ID: 21048983
[TBL] [Abstract][Full Text] [Related]
18. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
19. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.
Li Z; Wang H; Xue L; Shin DM; Roopenian D; Xu W; Qi CF; Sangster MY; Orihuela CJ; Tuomanen E; Rehg JE; Cui X; Zhang Q; Morse HC; Morris SW
Blood; 2009 Nov; 114(19):4158-68. PubMed ID: 19696203
[TBL] [Abstract][Full Text] [Related]
20. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
Yan Q; Huang Y; Watkins AJ; Kocialkowski S; Zeng N; Hamoudi RA; Isaacson PG; de Leval L; Wotherspoon A; Du MQ
Haematologica; 2012 Apr; 97(4):595-8. PubMed ID: 22102703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
